<DOC>
	<DOCNO>NCT01360658</DOCNO>
	<brief_summary>Solar urticaria rare debilitate disease severely impact quality life , restrict outdoor activities.Treatment , base sun protection anti-histaminic drug , efficacious 2 patient 3 . In refractory patient , photodesensitization immunosuppressive treatment cyclosporin A propose . As idiopathic urticaria , intravenous immunoglobulin ( IVIG ) show , retrospective study 7 patient , dramatically improve 71 % patient . In open-label prospective multicenter study , aim demonstrate efficacy single IVIG administration ( 2g/kg ) 10 patient affect severe refractory solar urticaria .</brief_summary>
	<brief_title>Intravenous Immunoglobulins Severe Refractory Solar Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>social insurance sign inform consent solar urticaria ( SU ) confirm photoexplorations SU involve face generalize whole body accompany bronchospasm trigger artificial light per annual SU SU alter quality life SU resistant photoprotection SU resistant association two different antihistaminics 3 month Pregnancy Heat trigger urticaria Contraindications IVIG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Intravenous immunoglobulin</keyword>
	<keyword>Solar urticaria</keyword>
	<keyword>Minimal urticaria dose</keyword>
	<keyword>Quality life</keyword>
	<keyword>Safety</keyword>
</DOC>